Want to see HK:6609 full AI Analyst Report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Stock Statistics & Valuation Metrics
Total Valuation
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has a market cap or net worth of HKD 2.18B. The enterprise value is HKD 664.27M.
- Market Cap
- HKD 2.18B
- Enterprise Value
- HKD 664.27M
Share Statistics
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,565,804
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 3.54%.
- Return on Equity (ROE)
- 0.07
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 3.54%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 960.67K
- Profits Per Employee
- 196.08K
- Employee Count
- 425
- Asset Turnover
- 0.32
- Inventory Turnover
- 0.82
Valuation Ratios
The current PE Ratio of Shanghai Heartcare Medical Technology Corp. Ltd. Class H is 18.17. Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s PEG ratio is 0.14.
- PE Ratio
- 18.17
- PS Ratio
- 3.60
- PB Ratio
- 1.40
- Price to FCF
- 18.97
- Price to Operating Cash Flow
- 16.11
- PEG Ratio
- 0.14
Income Statement
In the last 12 months, Shanghai Heartcare Medical Technology Corp. Ltd. Class H had revenue of 408.29M and earned 83.33M in profits. Earnings per share was 2.21.
- Revenue
- 408.29M
- Gross Profit
- 272.17M
- Operating Income
- 44.28M
- Pretax Income
- 86.41M
- Net Income
- 83.33M
- EBITDA
- 72.56M
- Earnings Per Share (EPS)
- 2.21
Cash Flow
In the last 12 months, operating cash flow was 105.51M and capital expenditures -7.90M, giving a free cash flow of 97.61M billion.
- Operating Cash Flow
- 105.51M
- Free Cash Flow
- 97.61M
- Free Cash Flow per Share
- 2.59
Dividends & Yields
Shanghai Heartcare Medical Technology Corp. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.29%
- Earnings Yield
- 5.46%
Stock Price Statistics
- Beta
- 0.84
- 52-Week Price Change
- -0.65%
- 50-Day Moving Average
- 52.23
- 200-Day Moving Average
- 48.83
- Relative Strength Index (RSI)
- 49.76
- Average Volume (3m)
- 41.60K
Important Dates
Shanghai Heartcare Medical Technology Corp. Ltd. Class H upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Shanghai Heartcare Medical Technology Corp. Ltd. Class H as a current ratio of 11.49, with Debt / Equity ratio of 3.77%
- Current Ratio
- 11.49
- Quick Ratio
- 9.74
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -7.54
- Interest Coverage Ratio
- 21.48
Taxes
In the past 12 months, Shanghai Heartcare Medical Technology Corp. Ltd. Class H has paid 3.07M in taxes.
- Income Tax
- 3.07M
- Effective Tax Rate
- 0.04
Enterprise Valuation
Shanghai Heartcare Medical Technology Corp. Ltd. Class H EV to EBITDA ratio is 12.14, with an EV/FCF ratio of 14.14.
- EV to Sales
- 2.69
- EV to EBITDA
- 12.14
- EV to Free Cash Flow
- 14.14
- EV to Operating Cash Flow
- 13.08
Balance Sheet
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has HKD 789.70M in cash and marketable securities with HKD 41.22M in debt, giving a net cash position of HKD 748.49M billion.
- Cash & Marketable Securities
- HKD 789.70M
- Total Debt
- HKD 41.22M
- Net Cash
- HKD 748.49M
- Net Cash Per Share
- HKD 23.71
- Tangible Book Value Per Share
- HKD 31.25
Margins
Gross margin is 68.81%, with operating margin of 19.11%, and net profit margin of 18.05%.
- Gross Margin
- 68.81%
- Operating Margin
- 19.11%
- Pretax Margin
- 21.47%
- Net Profit Margin
- 18.05%
- EBITDA Margin
- 22.13%
- EBIT Margin
- 17.43%
Analyst Forecast
The average price target for Shanghai Heartcare Medical Technology Corp. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 59.30%
- EPS Growth Forecast
- 131.03%
Scores
- Smart Score
- 7
- AI Score
- 73